title: [Mixed mullerian tumours of the endometrium. Retrospective study, with prognostic aims, comparing their evolution to that of adenocarcinomas of the endometrium].
abstract: Mixed Mullerian Tumours (MMT) of the endometrium have a bad reputation as far as prognosis is concerned. We have studied 34 cases of MMT treated between 1976 and 1988 and have compared their outcome with a matched series of 68 cases of adenocarcinoma (ADC). These were taken out of 880 cases of ADC treated during this period of time after matching them for the stage, the type of treatment, the year of treatment and the age of the patient. The curves of survival and the totals of survival were determined using Kaplan-Meier's method and also compared using Logrank's test. The 5-years overall survival was 18% for MMT as against 55% for ADC (p less than 0.001). The difference was equally significant statistically in terms of specific survival without recurrences. The 16 patients in stages I and II who were treated with the same protocol as used for ADC were matched against 32 cases of ADC taken out of the 680 cases ADC in stages I and II and treated by the same protocol (84%). After five years MMT had a higher number of survivors (35% overall, 45% with specific survival and 35% without recurrences), but the difference with survival of ADC was as significant (respectively 75, 85, 85%). Recurrences of MMT were frequent (62%), with metastases in 9 out of 10 and early (50%), in every respect opposed with recurrences of ADC (16%) which were in three out of five cases localized and late (after 10 months). These figures make one have to think of modifying the way MMT is treated. External pelvic radiotherapy should be carried out before any other treatment. The place for other methods of therapy is to be discussed.
authors.affiliation: Centre de lutte contre le Cancer, Vandoeuvre-lès-Nancy.
authors.forename: D
authors.initials: D
authors.lastname: Peiffert
authors.forename: M
authors.initials: M
authors.lastname: Pernot
authors.forename: F
authors.initials: F
authors.lastname: Guillemin
authors.forename: E
authors.initials: E
authors.lastname: Luporsi
authors.forename: R M
authors.initials: RM
authors.lastname: Parache
authors.forename: B
authors.initials: B
authors.lastname: Legras
authors.forename: P
authors.initials: P
authors.lastname: Bey
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000592:standards; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007044:Hysterectomy / Q000592:standards; D008875:Middle Aged; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D011878:Radiotherapy / Q000592:standards; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
vernacular_title: Les tumeurs mixtes mullériennes de l'endomètre. Etude rétrospective, à visée pronostique, comparant leur évolution à celle des adénocarcinomes de l'endomètre.